Back

Repetitive LevosimenDan infusions fOR patients with advanced chronic heart failure in the vulnerable post-discharge period: the multinational randomized LeoDOR trial

28 August 2023 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: HFrEF pathophysiology Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Associate Professor Gerhard Polzl

Innsbruck Medical University, Innsbruck (Austria)

6 More presentations in this session

Presentation thumbnail
Deep learning model to identify potential occurrence of reduced LVEF in patients with implantable loop recorders
Doctor J. Howard (London, GB)
Abstract Slides Video
Presentation thumbnail
Effect of vericiguat on cardiovascular outcomes in patients with heart failure with and without diabetes: Insights from the VICTORIA trial
Doctor J. Butler (Dallas, US)
Abstract Slides Video
Presentation thumbnail
The effect of iron deficiency treatment with intravenous ferric carboxymaltose on the arrhythmic burden of patients with HFrEF and cardiac implantable electronic devices
Mr A. Tsarouchas (Mistelbach, AT)
Abstract Slides Video
Presentation thumbnail
Prognostic value of three iron deficiency definitions in patients with advanced heart failure
Doctor J. Reinhold (Norwich, GB)
Abstract Slides Video
Presentation thumbnail
Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: determinants and relationship with patient-reported health status
Doctor J. Larsen (Odense, DK)
Abstract Slides Video

Access the full session

Session thumbnail
HFrEF pathophysiology

The Event

Event poster

ESC Congress 2023

28 August 2023 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Intermittent levosimendan in advanced palliative heart failure improves quality of life and reduces heart failure decompensations: a single center-experience
thumbnail
Congress Presentation
Trend of echocardiographic parameters, ventricular-arterial coupling, and biomarkers in advanced heart failure patients undergoing intermittent home-based levosimendan infusion
thumbnail
Congress Presentation
The role of intermittent levosimendan infusions in patients with advanced heart failure: is it enough?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources